Tuesday, Feb 15, 2022: 11:17 AM - 11:25 AM MST
Denver - Virtual Conference
Abstract Submission Number:
Late Breaking Abstract
Kenneth Ngure1, Gonasagrie Nair2, Daniel Szydlo3, Elizabeth R. Brown3, Carolyne Akello4, Pippa Macdonald5, Thesla Palanee-Phillips6, Bekezela Siziba7, Sharon L. Hillier8, Morgan Garcia9, Sherri Johnson9, Lisa Levy9, Tara McClure9, Lydia Soto-Torres10, Connie L. Celum11
1Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya, 2Stellenbosch University, Stellenbosch, South Africa, 3Fred Hutchinson Cancer Research Center, Seattle, WA, United States, 4Makerere University–Johns Hopkins University Research Collaboration, Kampala, Uganda, 5Desmond Tutu HIV Foundation, Cape Town, South Africa, 6Wits Reproductive Health and HIV Institute, Johannesburg, South Africa, 7University of Zimbabwe, Harare, Zimbabwe, 8University of Pittsburgh, Pittsburgh, PA, United States, 9FHI 360, Durham, NC, United States, 10National Institute of Allergy and Infectious Diseases, Rockville, MD, United States, 11University of Washington, Seattle, WA, United States
Adolescent girls and young women (AGYW) account for most new HIV acquisitions in Africa. WHO has recommended oral PrEP and the monthly dapivirine vaginal ring (ring) for women at risk of HIV acquisition. Given the need for high adherence for effectiveness and lower adherence among AGYW in efficacy trials, we assessed choice of and adherence to the ring and oral PrEP among African AGYW in the MTN-034/REACH crossover trial.
REACH enrolled 247 HIV-negative, non-pregnant AGYW ages 16-21 from South Africa, Zimbabwe, and Uganda from February 2019 to April 2021. Participants were randomized to the monthly ring or daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for the first 6 month period, then switched to the other product for the second 6 month period. Participants were given a choice of ring, oral PrEP, or neither in the third 6 month period. Adherence was measured by residual drug levels in returned used rings and dried blood spots (DBS) for oral PrEP, and is shown by proportion of visits. Dapivirine (DPV) release of <0.9mg indicate non-use, 0.9 to >4.0mg some use, and ≥4.0mg consistent with 28 days of use. Tenofovir diphosphate (TFV-DP) levels of <16 fmol/DBS punch indicates no use, 16-700 fmol/punch moderate and ≥700 fmol/punch high adherence. The proportion of visits with high adherence was compared between the cross-over and choice periods for each product.
Participants' average age was 18 years, and of 227 (92%) who continued in the choice period, 152 (67%) chose the ring, 71 (31%) oral PrEP, and 4 (2%) neither. Randomization sequence in the crossover period did not influence product choice. Residual DPV levels in used rings and TFV-DP levels in DBS showed participants had some to high use of the ring and moderate to high adherence to oral PrEP with <5% of visits with no adherence (Figure 1). High adherence to oral PrEP in the crossover period was strongly associated with choice of oral PrEP (p<0.001); an association was not observed for rings (p=0.85).
In the choice period among African AGYW who had 6 months use of both the ring and oral PrEP, 2/3 opted to use the ring; those with high adherence to oral PrEP in the crossover periods were likely to choose oral PrEP. Drug levels indicate partial to high adherence to both the ring and oral PrEP, higher than in prior studies. AGYW can make informed choices about HIV prevention products and are motivated to continue to use a product of their preference after previous oral PrEP or ring use.
(V) HIV Prevention Interventions in Adults
Adolescent girls and young women
Prior Presentation or Publication: In general, CROI does not accept work that has been previously published or publicly presented, or that is scheduled to be published or presented prior to CROI. Consideration may be given to a previously presented submission if meaningful newer data or different analyses are included, or if the prior or anticipated presentation was or will be at a conference not focused on HIV, viral hepatitis, or SARS-CoV-2-related topics. Electronic publication ahead of print that has been peer-reviewed and made generally accessible to the public is considered publication. Have your study data or abstract information been published, submitted for publication (where publication is anticipated on or before the start of the CROI where you will present), or presented at any other major national or international scientific or medical HIV-related conferences (ie, generally 400 or more attendees)?
Is the presenting author of this abstract a New Investigator (undergraduate students, graduate students, or postdoctoral fellow)? Note, this does not constitute for a New Investigator Scholarship application as applications are not being accepted during the Late-Breaking Abstract submission period. New Investigators will have a special designation on CROI materials (eg, CROI Program and Information Guide, Abstract eBook, etc).